DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Phase 1 Study of Zoledronic Acid in Sickle Cell Disease

Information source: Virginia Commonwealth University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Sickle Cell Disease

Intervention: Placebo (Drug); Zoledronic Acid (Drug)

Phase: Phase 1/Phase 2

Status: Withdrawn

Sponsored by: Virginia Commonwealth University

Official(s) and/or principal investigator(s):
John D Roberts, M.D., Principal Investigator, Affiliation: Virginia Commonwealth University

Summary

The long-term goal of this study is to learn if Zoledronic Acid can prevent or reduce pain in sickle cell disease. The goal of this study is to learn about the safety of Zoledronic Acid in persons with sickle cell disease who experience chronic pain requiring medical treatment or use of narcotics.

Clinical Details

Official title: Phase 1 Study of Zoledronic Acid in Sickle Cell Disease

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)

Primary outcome: The long-term goal of this project is to learn if Zoledronic Acid can prevent or reduce pain in sickle cell disease.

Secondary outcome: The specific purposes of this study are to learn if Zoledronic Acid has serious side effects for subjects with sickle cell disease and to study the effects of Zoledronic acid in subjects with sickle cell disease.

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 18 years and older

- Male or female with sickle cell disease

- Pain related to sickle cell disease Patient history of health services utilization

for acute SCD-related pain Patient history of use of narcotic analgesics for pain control within the past 6 months

- Able to tolerate hydration with 500 mL D51/2 NS prior to Zoledronic Acid or placebo

Exclusion Criteria:

- Calculated creatinine clearance less than 60 mL/min

- Current active dental problems

- Recent (within 6 weeks) or planned dental or jaw surgery (e. g., extraction,implants)

- History of cirrhosis or chronic symptomatic liver disease; acute liver disease

- History of aspirin-induced asthma

- History of allergy to zoledronic acid or similar chemical-entities

- Pregnant or nursing

- No prior bisphosphonate use

- Receipt of an investigational drug within 30 days

Locations and Contacts

Virginia Commonwealth University, Richmond, Virginia 23298, United States
Additional Information

Starting date: June 2007
Last updated: November 10, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017